Summary by Moomoo AI
Tengshengbo Pharmaceutical Biotechnology Co., Ltd. announced its interim report on June 30, 2024, with a loss of 283.2 million yuan during the period, an increase from 196.8 million yuan in the same period last year. The company's research and development expenses were 126.2 million yuan, and administrative expenses were 78.6 million yuan. There was no income during the period, but other income was 70.9 million yuan, mainly from government subsidies and bank interest. The company continues to advance the development of HBV candidate drug combinations and important transactions with partners Vir and VBI. The company's shares were listed on the Main Board of the Hong Kong Stock Exchange on July 13, 2021, and no dividends were distributed during the reporting period.
